Albireo Pharma, Inc. (NASDAQ: ALBO) dropped 23.5% to $19.00 after the company reported worse-than-expected Q2 EPS results and filed for a mixed shelf of up to $400 million.
Wedbush analyst Andreas Argyrides maintains Albireo Pharma (NASDAQ: ALBO) with a Outperform and lowers the price target from $72 to $61.Wedbush analyst Andreas Argyrides maintains Albireo Pharma (NASDAQ:ALBO) with a Outperform and lowers the price ta
Albireo Pharma (NASDAQ:ALBO) reported its Q2 earnings results on Monday, August 15, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.